RBRaanan Berger

Raanan Berger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Raanan Berger has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical experience with pembrolizumab in metastatic heavily pre-treated patients with solid cancers in a single center.

    by Raya Leibowitz-Amit, Einat Shacham-Shmueli, Talia Golan, Iris Gluck, Amir Onn, Leor Zach, Rony Weitzen, Einav Nili Gal-Yam, Damien Urban, Jair Bar, et al.

    E14549 Background: Pembrolizumab (pembro), an anti-PD1 monoclonal antibody, was recently approved for melanoma and NSCLC. Early signals of pembro activity were observed in several other solid cancers. Following this, and in accord with the concept of ‘the patient’s right to try’, our institutional ethical board approved it for off—label use in metastatic heavily pretreated cancer patients (pts). Our primary aim was to retrospectively assess the subjective clinical and radiological responses to pembro in this heterogeneous population. Methods: All non-hematological, non-melanoma adult ( > 18 years) cancer pts who received pembro (1-2 mg/kg, every 3 weeks) off-trial were retrospectively identified using pharmacy and electronic medical records. Radiological response was defined as a complete or partial decrease in tumor burden on computerized scans that was deemed clinically meaningful. Descriptive statistics were calculated with medians and percentages (Excel, Microsoft). Results: From Sep-14 to Dec-15, 96 pts received pembro off-trial. Pts were generally heavily pretreated (a median of 2 prior treatment lines) with compromised performance status. Pts were treated for a wide range of malignancies, including urothelial (17%), gastric (13%), ovarian (12%), NSCLC (13%) and cervical (9%) cancers. Median number of treatment cycles was 3 (range 1-13). Treatment was stopped in 54 pts (56%) due to clinical deterioration or death before radiological assessment. Fourteen pts (15%) had subjective clinical benefit on treatment. Two pts (2%) had radiological complete response and seven (7%) had partial radiological response; The response rate (RR) for the entire cohort was 9%. No responses were observed in 35 pts with ECOG PS = 3/4 (table). The RR associated with pembro when given as first or second line was 16% (7/43 pts) and 4% (2/51 pts) when given as third line or higher. Conclusions: Pembro has modest activity in non-selected, heavily pre-treated pts with metastatic solid malignancies. Poor performance status is associated with lack of response to Pembro.

  • Open Access

    Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial

    by Raya Leibowitz-Amit, Melania Pintilie, Leila Khoja, Arun A. Azad, Raanan Berger, A. Douglas Laird, Dana T. Aftab, Kim N. Chi, Anthony M. Joshua

    Cabozantinib is an orally available inhibitor of tyrosine kinases including VEGFR2 and c-MET. We performed a post hoc analysis to find associations between select plasma biomarkers and treatment response in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) who received cabozantinib 100 mg daily as part of a phase 2 non-randomized expansion cohort (NCT00940225). Plasma samples were collected at baseline, 6 weeks and at time of maximal response from 81 mCRPC pts with bone metastases, of which 33 also had measurable soft-tissue disease. Levels of 27 biomarkers were measured in duplicate using enzyme-linked immunosorbent assay. Spearman correlation coefficients were calculated for the association between biomarker levels or their change on treatment and either bone scan response (BSR) or soft tissue response according to RECIST. A BSR and RECIST response were seen in 66/81 pts (81 %) and 6/33 pts (18 %) respectively. No significant associations were found between any biomarker at any time point and either type of response. Plasma concentrations of VEGFA, FLT3L, c-MET, AXL, Gas6A, bone-specific alkaline phosphatase, interleukin-8 and the hypoxia markers CA9 and clusterin significantly increased during treatment with cabozantinib irrespective of response. The plasma concentrations of VEGFR2, Trap5b, Angiopoietin-2, TIMP-2 and TIE-2 significantly decreased during treatment with caboznatinib. Our data did not reveal plasma biomarkers associated with response to cabozantinib. The observed alterations in several biomarkers during treatment with cabozantinib may provide insights on the effects of cabozantinib on tumor cells and on tumor micro-environment and may help point to potential co-targeting approaches.


  • Association of changes in biomarkers with treatment with cabozantinib (Cabo) in metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the 100mg nonrandomized expansion cohort of a randomized discontinuation trial.

    by Raya Leibowitz-Amit, Melania Pintilie, A. Douglas Laird, Dana T. Aftab, Raanan Berger, Kim N. Chi, Anthony M. Joshua

    196 Background: Cabo, an oral inhibitor of receptor tyrosine kinases (RTK) including MET and VEGFR2, showed activity in early clinical studies in mCRPC, and is being investigated in phase 3 trials. Our primary aim was to retrospectively study the potential association between plasma concentrations of known markers of hypoxia, RTK cell signaling, inflammation, bone metabolism, chemo-attraction and epithelial-mesenchymal transition with response to Cabo in patients (pts) who received 100mg daily as part of a phase 2 non-randomized expansion cohort (NCT00940225). Methods: Our cohort of mCRPC pts with available plasma samples comprised of 81 pts with bone lesions assessed for bone scan response (BSR, defined as ≥30% decrease in lesion area compared to baseline). Thirty three pts also had measurable disease and were assessed for RECIST response. Plasma samples were available for all pts at baseline, at 6 weeks and at time of best response. Levels of 27 plasma biomarkers were measured in duplicate using ELISA. Spearman correlation coefficients were calculated for the association between response and biomarker levels at each time point. Results: Sixty six of 81 pts (81%) had a BSR, and 6 of 33 pts (18%) had a partial response by RECIST. No significant associations were found between the levels of any of the biomarkers at baseline or subsequent time points and either BSR or response by RECIST. Over time, the plasma concentrations of soluble VEGFR2 were significantly decreased during treatment with Cabo, consistent with the known effects of VEGFR inhibition on soluble VEGFR2. The plasma concentrations of nine markers (VEGFA, CA9, clusterin, FLT3L, Gas6A, Bone Alkaline phosphatase, and the soluble forms of the RTKs MET, IGF1R and AXL) were significantly increased during treatment with Cabo irrespective of response. Conclusions: These results demonstrate that metabolic alterations occur following treatment with Cabo in pts with mCRPC. Changes in certain biomarkers during treatment with Cabo could suggest potential co-targeting approaches with Cabo or other RTK inhibitors in mCRPC.


  • Using micro-RNA expression to predict response to neoadjuvant chemotherapy in urothelial carcinoma of the bladder.

    by Raya Leibowitz-Amit, Eduard Fridman, Noa Bossel, Liron Zehavi, Damien Urban, Yehudit Cohen, Zohar A. Dotan, Eytan Domany, Raanan Berger

    299 Background: Urothelial carcinoma of the bladder is among the 5 most common cancers in the US. Despite several clinical trials attempting to determine the best approach to muscle-invasive disease, the optimal treatment modalities and their sequence have not been established. Specifically, the decision to administer neo-adjuvant chemotherapy is currently based solely on clinical parameters, with no validated biomarkers. Micro-RNAs (miRNAs) are short RNA molecules that have roles in post-transcriptional gene expression regulation by binding to mRNAs. They were shown to have cardinal roles in many cancers, and their potential to serve as biomarkers is extensively studied. Our goal was to study whether miRNAs can serve as predictive biomarkers for response to neo-adjuvant chemotherapy in urothelial carcinoma. Methods: miRNAs were extracted from paraffin-embedded pre-operative muscle-invasive tumor biopsies of patients diagnosed with urothelial carcinoma, whose pathological surgical specimen was later found to either show complete or no-response to neo-adjuvant chemotherapy (termed 'responders' and 'non-responders', respectively). The expression pattern of approximately 900 miRNAs was compared using a commercial miRNA array, and the levels of candidate miRNAs was further assessed by quantitative real-time PCR (qRT-PCR). Results: The vast majority of miRNAs exhibited a similar expression pattern in the two patient groups, but two miRNAs were significantly lower in the responders (p

  • Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel (D).

    by Avivit Peer, Maya Ish-Shalom, Natalie Maimon, Maya Gottfried, Ben Boursi, Raya Leibowitz-Amit, Raanan Berger, Avivit Neumann, Svetlana Kovel, Avishay Sella, et al.

    146 Background: Abi is a standard treatment (tx) in pts with mCRPC refractory to deocetaxel. It is a potent and selective CYP 17 inhibitor that blocks the synthesis of androgens in the testis, adrenal glands, and prostate. However, in many countries where abi has not been approved yet, keto is used as an alternative CYP 17 inhibitor. Although preclinical data suggests that keto is a less specific and potent inhibitor of CYP 17, there are limited clinical data comparing both agents. We aimed to compare the clinical effectiveness of abi vs keto in pts with mCRPC refractory to D. Methods: Records from 156 mCRPC pts treated with keto 200 - 400 mg 3x day, in 4 centers across the US and Israel, were reviewed retrospectively. 26 pts treated post D were individually matched by clinicopathologic factors to pts treated with abi (selected from a multicenter Israeli database, n=120). We compared the PSA response (decrease ≥50% from baseline), biochemical and radiological progression free survival, and overall survival between the groups. Progression free survival and overall survival were determined by Cox regression. Results: The groups were matched by Gleason score, pre-tx disease extent (limited-axial skeleton and/or nodal vs extensive- appendicular skeleton and/or visceral), ECOG PS, pre-tx risk category (favorable, intermediate, poor; Keizman, Oncologist 2012). Furthermore, they were balanced regarding median age (71 abi vs 69 keto), time from primary tx to disease relapse, time to progression on prior GnRH-a and antiandrogen, PSA response and time to progression on prior D, pre-tx pain score/alkaline phosphatase/hemoglobin/ neutrophil to lymphocyte ratio/PSADT/PSA. In the groups of abi vs keto, PSA response was 46% vs 19% (OR 4.4, p=0.043), median biochemical PFS 7 vs 2 months (HR 0.65, p=0.02), median radiological PFS 6 vs 2.5 months (HR 0.63, p=0.016), median overall survival 17 vs 12 months (HR 0.53, p=0.79), and tx interruption d/t adverse events 12% vs 23% (0R 0.6, p=0.023). Conclusions: In mCRPC refractory to D, the outcome of pts treated with abiraterone was superior to ketoconazole.